Graphite Bio, Inc. is a clinical-stage, gene editing company. The Company is developing a new class of therapies to cure a range of serious and life-threatening diseases. Its gene-editing platform allows to correct mutations, replace entire disease-causing genes with normal genes, or insert new genes into predetermined, safe locations. The Company's lead product candidate, GPH101, is a differentiated approach with...